Sara Kalkhoran1,2,3, Joanna M Streck1,2,4,5, Gina R Kruse1,2,3, Nancy A Rigotti1,2,3, Giselle K Perez2,3,4,5, Susan Regan1,2, Colin J Ponzani3, Alona Muzikansky6, Elyse R Park1,2,3,4,5, Jamie S Ostroff7. 1. Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. The Mongan Institute, Massachusetts General Hospital, Boston, MA, USA. 4. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 5. Health Promotion and Resiliency Intervention Research (HPRIR) Program, Massachusetts General Hospital, Boston, MA, USA. 6. MGH Center for Biostatistics, Boston, MA, USA. 7. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
INTRODUCTION: Many cancer patients who smoke report concurrent e-cigarette use. Using a mixed-methods approach, we aimed to (1) describe longitudinal e-cigarette use over 6 months after a cancer diagnosis and (2) assess the association between e-cigarette use and smoking cessation, among cancer patients in a smoking cessation trial. AIMS AND METHODS: Data were from a 2-site randomized controlled trial of Standard (brief counseling) versus Intensive treatment (sustained counseling plus smoking cessation medication) in individuals who smoke recently diagnosed with cancer. Participants (n = 303) reported e-cigarette use at baseline, 3 months, and 6 months. Biochemically-verified past 7-day cigarette abstinence was collected at 6 months. Qualitative interviews at 6 months explored factors related to e-cigarette use. RESULTS: E-cigarette use prevalence was highest between baseline and 3 months (16%) and declined over time. Participants using e-cigarettes at follow-up had higher baseline cigarette dependence and smoked more heavily. Multivariable analyses found no significant association between follow-up e-cigarette use and 6-month cigarette abstinence. E-cigarette use at follow-up was higher in the Standard versus Intensive treatment group (p = .003 and .001 at 3 and 6 mo, respectively). Smoking cessation and health concerns were primary reasons for using e-cigarettes. CONCLUSIONS: Among individuals who smoke recently diagnosed with cancer and enrolled in a smoking cessation intervention trial, e-cigarette use during trial participation was not associated with smoking abstinence. Individuals who chose to use e-cigarettes were less likely to be receiving intensive cessation support as part of the trial. Further studies are needed to evaluate the association between e-cigarette use and smoking cessation in cancer patients. IMPLICATIONS: E-cigarette use was not associated with cigarette abstinence at 6 months among adults who smoke recently diagnosed with cancer enrolled in a smoking cessation trial. Individuals with easier access to evidence-based smoking cessation treatment may be less likely to use e-cigarettes.
INTRODUCTION: Many cancer patients who smoke report concurrent e-cigarette use. Using a mixed-methods approach, we aimed to (1) describe longitudinal e-cigarette use over 6 months after a cancer diagnosis and (2) assess the association between e-cigarette use and smoking cessation, among cancer patients in a smoking cessation trial. AIMS AND METHODS: Data were from a 2-site randomized controlled trial of Standard (brief counseling) versus Intensive treatment (sustained counseling plus smoking cessation medication) in individuals who smoke recently diagnosed with cancer. Participants (n = 303) reported e-cigarette use at baseline, 3 months, and 6 months. Biochemically-verified past 7-day cigarette abstinence was collected at 6 months. Qualitative interviews at 6 months explored factors related to e-cigarette use. RESULTS: E-cigarette use prevalence was highest between baseline and 3 months (16%) and declined over time. Participants using e-cigarettes at follow-up had higher baseline cigarette dependence and smoked more heavily. Multivariable analyses found no significant association between follow-up e-cigarette use and 6-month cigarette abstinence. E-cigarette use at follow-up was higher in the Standard versus Intensive treatment group (p = .003 and .001 at 3 and 6 mo, respectively). Smoking cessation and health concerns were primary reasons for using e-cigarettes. CONCLUSIONS: Among individuals who smoke recently diagnosed with cancer and enrolled in a smoking cessation intervention trial, e-cigarette use during trial participation was not associated with smoking abstinence. Individuals who chose to use e-cigarettes were less likely to be receiving intensive cessation support as part of the trial. Further studies are needed to evaluate the association between e-cigarette use and smoking cessation in cancer patients. IMPLICATIONS: E-cigarette use was not associated with cigarette abstinence at 6 months among adults who smoke recently diagnosed with cancer enrolled in a smoking cessation trial. Individuals with easier access to evidence-based smoking cessation treatment may be less likely to use e-cigarettes.
Authors: John B Correa; Karen O Brandon; Lauren R Meltzer; Hannah J Hoehn; Bárbara Piñeiro; Thomas H Brandon; Vani N Simmons Journal: Psychooncology Date: 2018-04-25 Impact factor: 3.894
Authors: Thomas H Brandon; Maciej L Goniewicz; Nasser H Hanna; Dorothy K Hatsukami; Roy S Herbst; Jennifer A Hobin; Jamie S Ostroff; Peter G Shields; Benjamin A Toll; Courtney A Tyne; Kasisomayajula Viswanath; Graham W Warren Journal: J Clin Oncol Date: 2015-01-08 Impact factor: 44.544
Authors: David J K Balfour; Neal L Benowitz; Suzanne M Colby; Dorothy K Hatsukami; Harry A Lando; Scott J Leischow; Caryn Lerman; Robin J Mermelstein; Raymond Niaura; Kenneth A Perkins; Ovide F Pomerleau; Nancy A Rigotti; Gary E Swan; Kenneth E Warner; Robert West Journal: Am J Public Health Date: 2021-08-19 Impact factor: 9.308
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226